Financial Snapshot

Revenue
$12.69M
TTM
Gross Margin
43.36%
TTM
Net Earnings
-$75.49M
TTM
Current Assets
Q4 2022
Current Liabilities
Q4 2022
Current Ratio
147.56%
Q4 2022
Total Assets
Q4 2022
Total Liabilities
Q4 2022
Book Value
$30.59M
Q4 2022
Cash
Q4 2022
P/E
-0.000001891
May 24, 2024 EST
Free Cash Flow
-$113.6M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2022 2021 2020

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2022 2021 2020

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2022 2021 2020

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021 2020

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2022 2021 2020

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

No data

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2022 2021 2020

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021 2020

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $142.74

About Pear Therapeutics, Inc.

Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The company is headquartered in Boston, Massachusetts and currently employs 200 full-time employees. The company went IPO on 2021-02-02. The firm is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The firm's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Company’s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The firm has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Industry: Services-Health Services Peers: Babylon Holdings Ltd CareCloud, Inc. TruBridge, Inc. Forian Inc. UpHealth, Inc. OptimizeRx Corp Tabula Rasa HealthCare, Inc. Akili, Inc.